- Coordinator
- Fundacio Centre De Regulacio Genomica, Spain
- Runs
- 1 March 2025 to 31 August 2026
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101213167
What the project is doing
In the project's own words, from its summary on CORDIS.
Peptide drugs potentially address limitations of both small molecules and antibodies. Small molecules struggle to target protein-protein interactions (PPIs), while antibodies cannot access intracellular proteins. In this project we will develop an AI-driven experimental platform to produce cell-permeable therapeutic peptides made entirely of natural amino acids. The platform will allow the rapid discovery of cost-effective, stable, cell-permeable, and high-affinity peptide binders for use as research tools, in diagnostics, and as therapeutics against intracellular proteins previously considered undruggable targets.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacio Centre De Regulacio Genomica | Barcelona | Spain | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI